Common beans are highly consumed worldwide; this legume has multiple colors and shapes and presents high protein content, carbohydrates, dietary fiber, minerals, and vitamins. Common beans also contain several bioactive components attracting consumer's attention in recent years due to their multiple benefits to human health. These bioactive components can be mainly classified under phenolic compounds (phenolic acid, flavonoids, anthocyanins, and tannins), carbohydrates, phytosterols, saponins, carotenoids, tocopherols, proteins, and peptides. Moreover, scientific evidence indicates that these bioactive components can regulate different metabolic pathways, including lipid and carbohydrate metabolism. Thus, bioactive components have been reported to modulate some inflammatory markers (tumor necrosis factor‐alpha [TNF‐α] and interleukins [IL‐6]), carbohydrate‐degrading enzymes (α‐amylase and α‐glucosidase), enzymes involved in fatty acid or cholesterol biosynthesis (acyl‐CoA synthase long‐chain fatty acid isoform 4 [ACSL4], acyl‐CoA dehydrogenase for long‐chain fatty acids [ACADL]), fatty acid translocase (CD36), and carnitine palmitoyltransferase 1 (CPT1)), as well as satiety‐related hormones. Therefore, common bean bioactive components exert great potential to modulate molecular markers related to noncommunicable diseases and can be used as adjuvants to prevent and treat obesity and type 2 diabetes (T2D). This chapter reviews the potential of common bean bioactive components to modulate obesity and T2D molecular markers.